Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675447 | 0.85 | ANPEP (0.34) | ANPEP | |
| SCHEMBL13673890 | 0.79 | LMNA (0.39) | LMNA | |
| SCHEMBL8227678 | 0.78 | — | — | |
| SCHEMBL14528628 | 0.78 | — | — | |
| SCHEMBL12321611 | 0.78 | — | — | |
| SCHEMBL23898861 | 0.76 | GSR (0.37) | ANPEPS1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL13675433 | 0.76 | S1PR2 (0.52) | LMNAS1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL14143218 | 0.76 | S1PR2 (0.52) | LMNAS1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL10290497 | 0.75 | LMNA (0.57) | LMNABLM | |
| SCHEMBL15551105 | 0.75 | ALDH1A1 (0.38) | ANPEPALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | PKD2, PKD1, AADAT | LMNA 2132/4885ANPEP 51/4885ALDH1A1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.